As Novartis Exits, Who Will Make New Antibiotics? Threat of Antibiotic Resistance Looms Large
Originally published on Genetic Engineering & Biotechnology News
Health officials have been sending a strong, collaborative message regarding the severity of the threat of antimicrobial resistance (AMR). The World Health Organization (WHO) warns that AMR is “one of the biggest threats to global health, food security, and development today.” While Tom Frieden, former director of the Centers for Disease Control and Prevention (CDC), adds "we need to act now, because we cannot know with certainty that we will have new or better drugs in the future."
Despite the current crisis, Novartis recently announced that it is terminating its antibacterial research at its Novartis Institutes for Biomedical Research (NIBR) campus in Emeryville, California, laying off 140 employees.
Why would the fourth largest pharma company, with an annual revenue of $49 billion, close down their program? Jenn Leeds, Ph.D., executive director and head of antibacterial discovery at NIBR tells GENthat, “The industry faces an impasse in bringing new antibacterial medicines to patients. The commercial model for anti-infectives is critically challenged, and we (like many others) are left questioning whether large pharma can sustainably support the required, significant infrastructure needed to discover, develop, and commercialize anti-infectives.” Leeds says that Novartis will “prioritize our resources in other areas where we believe we are better positioned to develop innovative medicines.”
Novartis is not the first big pharma company to leave antimicrobial research, with similar decisions having been made in the past by Bristol-Myers Squibb and AstraZeneca. Even Eli Lilly, one of the first companies to manufacture penicillin in the 1940s, followed by decades of continued success with the development of top-selling antibiotics such as vancomycin, erythromycin, Keflex, and Ceclor, has gotten out of the game.
Jayasree Iyer, Ph.D., executive director of Access to Medicine Foundation (AMF), tells GEN, “More and more, we are seeing a consolidation with companies leaving the market,” which she attributes to multiple factors including a “lack of incentives.” She says that “the sustained production of key antibiotics requires a big investment and because the price of antibiotics is low, the companies look toward other sources of funding.”
With some key players in Big Pharma closing their doors on antibacterial R&D, who is going to make new antibiotics?
Someone certainly needs to, with more than 2 million illnesses and 23,000 deaths in the United States every year (and an estimated 700,000 deaths worldwide) caused by AMR infections. Those numbers are expected to rise dramatically in the coming years.
Dr. Leeds offers that there are several groups that can be key players in novel antibiotic discovery. “Academic groups can help with target validation, with approaches to overcoming bacterial permeability and efflux barriers, with new chemistries, with novel approaches to manufacturing, and with patient stratification approaches. Small- and medium-sized enterprises (SMEs) can help with generation and validation of approaches by rigorous preclinical testing and testing novel approaches clinically.”
Indeed, SMEs are an important stakeholder in the future of AMR. Companies like Warp Drive Bio, Entasis Therapeutics, Nabriva Therapeutics, Symcel Sveridge (see sidebar) and Melinta Therapeutics (which recently merged with Cempra), are developing novel antibacterial therapies. In addition to compound development, SMEs are innovating new ways to think about AMR, shifting the paradigm of how these infectious diseases are treated. For example, the new biotech startup Arc Bio is launching an NGS-based AMR product that can annotate any Gram-negative bacterial DNA sequence in minutes.
Arc Bio CEO Todd Dickinson, Ph.D., says, “Rapid identification of various strains of antimicrobial resistance, and better understanding their transmission and evolution, is vital to protecting public health.”
AMF is an independent non-profit organization whose mission is to enact change in pharmaceutical companies’ focus on access to medicine, including antibiotics. One way that AMF accomplishes that goal is through the "Antimicrobial Resistance Benchmark", an independent and public tool that ranks how companies are addressing the needs defined by the CDC and WHO when developing antimicrobials.
The benchmark shows that some big pharma firms are still in the game. GlaxoSmithKline (GSK), Merck & Co., Pfizer, and Johnson & Johnson are among the names that Dr. Iyer mentions as retaining a dedicated commitment to antibiotic research and development.
These four companies are a handful of the roughly 100 companies and 15 industry associations that signed the "Davos Declaration” at the 2016 World Economic Forum committing to "reduce the development of antimicrobial resistance, invest in research and development of new treatments and diagnostics, and improve access to current and new antibiotics." Nine of the companies were also roadmap signatories, collaborating to define and committing to implement that progress. It should be noted that Novartis signed both the declaration and the roadmap.
Dr. Iyer stresses the need to incentivize companies to stay in the market. U.S. Food and Drug Administration (FDA) Commissioner Scott Gottlieb, M.D., agrees. In a statement made on July 12, Dr. Gottlieb announced the “formation of a new Drug Shortages Task Force” charged to “delve more deeply into the reasons why some shortages remain a persistent challenge.” He offers that one possible solution is to “look at regulations coupled with additional financial incentives to market these critical access drugs.”
Despite the shuttering of their R&D program, Novartis is working to find groups that can continue their ongoing projects. Dr. Leeds says that “these anti-infective medicines must reach patients. We are hard at work to identify partners beyond Novartis to carry these programs forward, as the public health crises of AMR is pressing.”
When asked where she thinks we will be in 2040 in our battle with AMR, Dr. Leeds answers, “On one hand, I’m very concerned that we will be facing bigger challenges with AMR, given increased globalization and travel, increased patient populations who are at risk for infection, and diminishing efficacy of existing drugs due to overuse or inappropriate use.” Dr. Leeds adds that, “On the other hand, I am hopeful that we can, as a community, pre-empt an even more serious crisis by tackling the various challenges in the AMR space with tangible and impactful actions.”
Dr. Leeds continues, “We need to be working on high quality, high value approaches, using the wealth of experience and data that already exist, so that we place our bets with the highest chances of success. Luck favors a prepared mind.”